There is no doubt that Allscripts Healthcare Solutions Inc. (MDRX) ticks all the boxes.

Allscripts Healthcare Solutions Inc. (NASDAQ: MDRX) stock fell -0.18% on Friday to $16.56 against a previous-day closing price of $16.59. With 1.28 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.27 million shares. During the session, the Health Information Services company that operates in wider Healthcare sector, reached to the highest price of $17.05 whereas the lowest price it dropped to was $16.54. The 52-week range on MDRX shows that it touched its highest point at $23.25 and its lowest point at $13.05 during that stretch. It currently has a 1-year price target of $22.11. Beta for the stock currently stands at 0.98.

Top 5 Tech Stocks Every Investor Should Buy Right Now

While finding excellent stocks with the potential for gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Tech Stocks Every Investor Should Buy Right Now", we have identified five tech stocks we believe could appreciate.

Sign up here to get your free report now.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MDRX was up-trending over the past week, with a rise of 0.30%, but this was down by -3.27% over a month. Three-month performance surged to 7.81% while six-month performance fell -25.47%. The stock gained 20.61% in the past year, while it has lost -10.24% so far this year. A look at the trailing 12-month EPS for MDRX yields 0.96 with Next year EPS estimates of 0.88. For the next quarter, that number is 0.19. This implies an EPS growth rate of 216.00% for this year and 10.57% for next year. EPS is expected to grow by 8.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 42.10%.

Float and Shares Shorts:

At present, 114.25 million MDRX shares are outstanding with a float of 108.11 million shares on hand for trading. On Jul 14, 2022, short shares totaled 10.98 million, which was 9.47% higher than short shares on Jun 14, 2022. In addition to Mr. Richard J. Poulton as the firm’s CEO & Director, Ms. Tejal Vakharia serves as its Sr. VP of Marketing & Gov. Affairs, Gen. Counsel and Chief Compliance Counsel.

Institutional Ownership:

Through their ownership of 106.14% of MDRX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 88.55% of MDRX, in contrast to 60.91% held by mutual funds. Shares owned by individuals account for 45.85%. As the largest shareholder in MDRX with 16.42% of the stake, BlackRock Fund Advisors holds 18,189,259 shares worth 18,189,259. A second-largest stockholder of MDRX, The Vanguard Group, Inc., holds 13,939,906 shares, controlling over 12.58% of the firm’s shares. Dimensional Fund Advisors LP is the third largest shareholder in MDRX, holding 9,372,570 shares or 8.46% stake. With a 7.78% stake in MDRX, the iShares Core S&P Small Cap ETF is the largest stakeholder. A total of 8,613,803 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 2.93% of MDRX stock, is the second-largest Mutual Fund holder. It holds 3,248,166 shares valued at 55.22 million. Vanguard Small Cap Index Fund holds 2.51% of the stake in MDRX, owning 2,785,383 shares worth 47.35 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for MDRX since 10 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 5 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With MDRX analysts setting a high price target of $26.00 and a low target of $18.00, the average target price over the next 12 months is $22.00. Based on these targets, MDRX could surge 57.0% to reach the target high and rise by 8.7% to reach the target low. Reaching the average price target will result in a growth of 32.85% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. MDRX will report FY 2022 earnings on 02/23/2023. Analysts have provided yearly estimates in a range of $1.05 being high and $0.68 being low. For MDRX, this leads to a yearly average estimate of $0.80. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Allscripts Healthcare Solutions Inc. surprised analysts by $0.03 when it reported $0.18 EPS against a consensus estimate of $0.15. The surprise factor in the prior quarter was -$0.13. Based on analyst estimates, the high estimate for the next quarter is $0.22 and the low estimate is $0.17. The average estimate for the next quarter is thus $0.19.

Summary of Insider Activity:

Insiders traded MDRX stock several times over the past three months with 5 Buys and 4 Sells. In these transactions, 63,780 shares were bought while 23,945 shares were sold. The number of buy transactions has increased to 10 while that of sell transactions has risen to 36 over the past year. The total number of shares bought during that period was 966,693 while 1,166,752 shares were sold.

Leave a Comment

Your email address will not be published.